Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0
Identifieur interne : 000951 ( Istex/Corpus ); précédent : 000950; suivant : 000952Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0
Auteurs : Edward L. Murphy ; Renaud Mahieux ; Guy De Thé ; Fredj Tekaia ; Dannie Ameti ; Jacqueline Horton ; Antoine GessainSource :
- Virology [ 0042-6822 ] ; 1998.
English descriptors
- KwdEn :
- Agarose, American indian, American indian blood donors, American indians, Amerindian, Blood donors, Bootstrap, Bootstrap iterations, Bootstrap values, Cohort, Current study, Defic, Demographic characteristics, Donor, Drug users, Endemic, Epidemiology, Ethidium bromide, Heneine, Hispanic, Human lymphotropic virus type, Human virus type, Immun, Intravenous drug users, Khabbaz, Kimura distance, Long terminal, Lymphotropic, Lymphotropic virus type, Major risk factors, Phylogenetic, Phylogenetic analysis, Phylogroup, Restriction fragment length polymorphism, Retrovir, Retrovirus epidemiology donor study, Rflp, Rflp type, Rflp types, Risk blood donors, Risk factors, Risk subjects, Sexual transmission, Switzer, Syndr.
- Teeft :
- Agarose, American indian, American indian blood donors, American indians, Amerindian, Blood donors, Bootstrap, Bootstrap iterations, Bootstrap values, Cohort, Current study, Defic, Demographic characteristics, Donor, Drug users, Endemic, Epidemiology, Ethidium bromide, Heneine, Hispanic, Human lymphotropic virus type, Human virus type, Immun, Intravenous drug users, Khabbaz, Kimura distance, Long terminal, Lymphotropic, Lymphotropic virus type, Major risk factors, Phylogenetic, Phylogenetic analysis, Phylogroup, Restriction fragment length polymorphism, Retrovir, Retrovirus epidemiology donor study, Rflp, Rflp type, Rflp types, Risk blood donors, Risk factors, Risk subjects, Sexual transmission, Switzer, Syndr.
Abstract
Molecular subtyping was used to investigate the epidemiology of human T-lymphotropic virus type II (HTLV-II) in the United States. Nested polymerase chain reaction of the HTLV-II long terminal repeat region followed by restriction fragment length polymorphism (RFLP) analysis was performed on HTLV-II seropositive subjects including 97 U.S. blood donors without major risk factors for HTLV-II infection, 53 injection drug users (IDU), and 10 American Indian blood donors. Three new HTLV-II RFLP types were confirmed with DNA sequencing and phylogenetic analysis. HTLV-II RFLP type a0 (Switzer classification) was associated with older age [adjusted odds ratio (OR) 1.06 per year of age, 95% confidence interval (CI) 1.02–1.09] and with Black (OR 5.24, 95% CI 1.90–14.47) and White (OR 4.43, 95% CI 1.67–11.75) race/ ethnicity. These data are consistent with an age–cohort effect for HTLV-II RFLP type a0 among older White and Black IDU and blood donors. This finding could be explained by an epidemic of non-a0 HTLV-II RFLP types among younger persons of Hispanic and other race/ethnicity, superimposed upon endemic HTLV-II RFLP type a0 among older Black and White persons.
Url:
DOI: 10.1006/viro.1997.9009
Links to Exploration step
ISTEX:6E7673E1DA630ABB7B43F1C7FD81517561532FDBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</title><author><name sortKey="Murphy, Edward L" sort="Murphy, Edward L" uniqKey="Murphy E" first="Edward L" last="Murphy">Edward L. Murphy</name><affiliation><mods:affiliation>Departments of Laboratory Medicine, Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, California, 94143</mods:affiliation></affiliation></author><author><name sortKey="Mahieux, Renaud" sort="Mahieux, Renaud" uniqKey="Mahieux R" first="Renaud" last="Mahieux">Renaud Mahieux</name><affiliation><mods:affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="De The, Guy" sort="De The, Guy" uniqKey="De The G" first="Guy" last="De Thé">Guy De Thé</name><affiliation><mods:affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Tekaia, Fredj" sort="Tekaia, Fredj" uniqKey="Tekaia F" first="Fredj" last="Tekaia">Fredj Tekaia</name><affiliation><mods:affiliation>Unité de Génétique Moléculaire des Levures, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Ameti, Dannie" sort="Ameti, Dannie" uniqKey="Ameti D" first="Dannie" last="Ameti">Dannie Ameti</name><affiliation><mods:affiliation>Westat Inc. Rockville, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Horton, Jacqueline" sort="Horton, Jacqueline" uniqKey="Horton J" first="Jacqueline" last="Horton">Jacqueline Horton</name><affiliation><mods:affiliation>Westat Inc. Rockville, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Gessain, Antoine" sort="Gessain, Antoine" uniqKey="Gessain A" first="Antoine" last="Gessain">Antoine Gessain</name><affiliation><mods:affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6E7673E1DA630ABB7B43F1C7FD81517561532FDB</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1006/viro.1997.9009</idno><idno type="url">https://api.istex.fr/document/6E7673E1DA630ABB7B43F1C7FD81517561532FDB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000951</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000951</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</title><author><name sortKey="Murphy, Edward L" sort="Murphy, Edward L" uniqKey="Murphy E" first="Edward L" last="Murphy">Edward L. Murphy</name><affiliation><mods:affiliation>Departments of Laboratory Medicine, Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, California, 94143</mods:affiliation></affiliation></author><author><name sortKey="Mahieux, Renaud" sort="Mahieux, Renaud" uniqKey="Mahieux R" first="Renaud" last="Mahieux">Renaud Mahieux</name><affiliation><mods:affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="De The, Guy" sort="De The, Guy" uniqKey="De The G" first="Guy" last="De Thé">Guy De Thé</name><affiliation><mods:affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Tekaia, Fredj" sort="Tekaia, Fredj" uniqKey="Tekaia F" first="Fredj" last="Tekaia">Fredj Tekaia</name><affiliation><mods:affiliation>Unité de Génétique Moléculaire des Levures, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Ameti, Dannie" sort="Ameti, Dannie" uniqKey="Ameti D" first="Dannie" last="Ameti">Dannie Ameti</name><affiliation><mods:affiliation>Westat Inc. Rockville, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Horton, Jacqueline" sort="Horton, Jacqueline" uniqKey="Horton J" first="Jacqueline" last="Horton">Jacqueline Horton</name><affiliation><mods:affiliation>Westat Inc. Rockville, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Gessain, Antoine" sort="Gessain, Antoine" uniqKey="Gessain A" first="Antoine" last="Gessain">Antoine Gessain</name><affiliation><mods:affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Virology</title><title level="j" type="abbrev">YVIRO</title><idno type="ISSN">0042-6822</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">242</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="425">425</biblScope><biblScope unit="page" to="434">434</biblScope></imprint><idno type="ISSN">0042-6822</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0042-6822</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agarose</term><term>American indian</term><term>American indian blood donors</term><term>American indians</term><term>Amerindian</term><term>Blood donors</term><term>Bootstrap</term><term>Bootstrap iterations</term><term>Bootstrap values</term><term>Cohort</term><term>Current study</term><term>Defic</term><term>Demographic characteristics</term><term>Donor</term><term>Drug users</term><term>Endemic</term><term>Epidemiology</term><term>Ethidium bromide</term><term>Heneine</term><term>Hispanic</term><term>Human lymphotropic virus type</term><term>Human virus type</term><term>Immun</term><term>Intravenous drug users</term><term>Khabbaz</term><term>Kimura distance</term><term>Long terminal</term><term>Lymphotropic</term><term>Lymphotropic virus type</term><term>Major risk factors</term><term>Phylogenetic</term><term>Phylogenetic analysis</term><term>Phylogroup</term><term>Restriction fragment length polymorphism</term><term>Retrovir</term><term>Retrovirus epidemiology donor study</term><term>Rflp</term><term>Rflp type</term><term>Rflp types</term><term>Risk blood donors</term><term>Risk factors</term><term>Risk subjects</term><term>Sexual transmission</term><term>Switzer</term><term>Syndr</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Agarose</term><term>American indian</term><term>American indian blood donors</term><term>American indians</term><term>Amerindian</term><term>Blood donors</term><term>Bootstrap</term><term>Bootstrap iterations</term><term>Bootstrap values</term><term>Cohort</term><term>Current study</term><term>Defic</term><term>Demographic characteristics</term><term>Donor</term><term>Drug users</term><term>Endemic</term><term>Epidemiology</term><term>Ethidium bromide</term><term>Heneine</term><term>Hispanic</term><term>Human lymphotropic virus type</term><term>Human virus type</term><term>Immun</term><term>Intravenous drug users</term><term>Khabbaz</term><term>Kimura distance</term><term>Long terminal</term><term>Lymphotropic</term><term>Lymphotropic virus type</term><term>Major risk factors</term><term>Phylogenetic</term><term>Phylogenetic analysis</term><term>Phylogroup</term><term>Restriction fragment length polymorphism</term><term>Retrovir</term><term>Retrovirus epidemiology donor study</term><term>Rflp</term><term>Rflp type</term><term>Rflp types</term><term>Risk blood donors</term><term>Risk factors</term><term>Risk subjects</term><term>Sexual transmission</term><term>Switzer</term><term>Syndr</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Molecular subtyping was used to investigate the epidemiology of human T-lymphotropic virus type II (HTLV-II) in the United States. Nested polymerase chain reaction of the HTLV-II long terminal repeat region followed by restriction fragment length polymorphism (RFLP) analysis was performed on HTLV-II seropositive subjects including 97 U.S. blood donors without major risk factors for HTLV-II infection, 53 injection drug users (IDU), and 10 American Indian blood donors. Three new HTLV-II RFLP types were confirmed with DNA sequencing and phylogenetic analysis. HTLV-II RFLP type a0 (Switzer classification) was associated with older age [adjusted odds ratio (OR) 1.06 per year of age, 95% confidence interval (CI) 1.02–1.09] and with Black (OR 5.24, 95% CI 1.90–14.47) and White (OR 4.43, 95% CI 1.67–11.75) race/ ethnicity. These data are consistent with an age–cohort effect for HTLV-II RFLP type a0 among older White and Black IDU and blood donors. This finding could be explained by an epidemic of non-a0 HTLV-II RFLP types among younger persons of Hispanic and other race/ethnicity, superimposed upon endemic HTLV-II RFLP type a0 among older Black and White persons.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>rflp</json:string><json:string>rflp type</json:string><json:string>rflp types</json:string><json:string>phylogenetic</json:string><json:string>bootstrap</json:string><json:string>lymphotropic</json:string><json:string>blood donors</json:string><json:string>switzer</json:string><json:string>amerindian</json:string><json:string>endemic</json:string><json:string>epidemiology</json:string><json:string>khabbaz</json:string><json:string>hispanic</json:string><json:string>phylogroup</json:string><json:string>agarose</json:string><json:string>cohort</json:string><json:string>retrovir</json:string><json:string>heneine</json:string><json:string>defic</json:string><json:string>syndr</json:string><json:string>immun</json:string><json:string>phylogenetic analysis</json:string><json:string>human virus type</json:string><json:string>human lymphotropic virus type</json:string><json:string>risk subjects</json:string><json:string>current study</json:string><json:string>risk blood donors</json:string><json:string>american indians</json:string><json:string>intravenous drug users</json:string><json:string>american indian</json:string><json:string>sexual transmission</json:string><json:string>lymphotropic virus type</json:string><json:string>demographic characteristics</json:string><json:string>american indian blood donors</json:string><json:string>drug users</json:string><json:string>long terminal</json:string><json:string>restriction fragment length polymorphism</json:string><json:string>risk factors</json:string><json:string>ethidium bromide</json:string><json:string>bootstrap iterations</json:string><json:string>retrovirus epidemiology donor study</json:string><json:string>kimura distance</json:string><json:string>major risk factors</json:string><json:string>bootstrap values</json:string><json:string>donor</json:string><json:string>black race</json:string><json:string>study population</json:string><json:string>point agarose</json:string><json:string>cohort effect</json:string><json:string>phylogenetic analyses</json:string><json:string>sequence information</json:string><json:string>other studies</json:string><json:string>dnapars program</json:string><json:string>endemic focus</json:string><json:string>child transmission</json:string><json:string>mega program</json:string><json:string>academic press</json:string><json:string>white persons</json:string><json:string>novel rflp types</json:string><json:string>bootstrap value</json:string><json:string>mexican prostitute</json:string><json:string>cameroonian prostitute</json:string><json:string>geographic location</json:string><json:string>younger subjects</json:string><json:string>higher proportion</json:string><json:string>subject group</json:string><json:string>metropolitan areas</json:string><json:string>molecular epidemiology</json:string><json:string>white race</json:string><json:string>endemic rflp type</json:string><json:string>high prevalence</json:string><json:string>blood transfusion</json:string><json:string>reds cohort</json:string><json:string>viral load</json:string><json:string>final concentration</json:string><json:string>kayapo indians</json:string><json:string>consensus tree</json:string><json:string>younger persons</json:string><json:string>confidence interval</json:string><json:string>cell lymphotropic virus type</json:string><json:string>human virus types</json:string><json:string>odds ratio</json:string><json:string>injection drug users</json:string><json:string>polymerase chain reaction</json:string><json:string>molecular subtyping</json:string><json:string>molecular characterization</json:string><json:string>nucleotide sequence</json:string><json:string>restriction fragment length polymorphism analysis</json:string><json:string>laboratory medicine</json:string><json:string>rflp subtype</json:string><json:string>restriction site</json:string></teeft></keywords><author><json:item><name>Edward L Murphy</name><affiliations><json:string>Departments of Laboratory Medicine, Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, California, 94143</json:string></affiliations></json:item><json:item><name>Renaud Mahieux</name><affiliations><json:string>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</json:string></affiliations></json:item><json:item><name>Guy de Thé</name><affiliations><json:string>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</json:string></affiliations></json:item><json:item><name>Fredj Tekaia</name><affiliations><json:string>Unité de Génétique Moléculaire des Levures, Institut Pasteur, Paris, France</json:string></affiliations></json:item><json:item><name>Dannie Ameti</name><affiliations><json:string>Westat Inc. Rockville, Maryland</json:string></affiliations></json:item><json:item><name>Jacqueline Horton</name><affiliations><json:string>Westat Inc. Rockville, Maryland</json:string></affiliations></json:item><json:item><name>Antoine Gessain</name><affiliations><json:string>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Molecular subtyping was used to investigate the epidemiology of human T-lymphotropic virus type II (HTLV-II) in the United States. Nested polymerase chain reaction of the HTLV-II long terminal repeat region followed by restriction fragment length polymorphism (RFLP) analysis was performed on HTLV-II seropositive subjects including 97 U.S. blood donors without major risk factors for HTLV-II infection, 53 injection drug users (IDU), and 10 American Indian blood donors. Three new HTLV-II RFLP types were confirmed with DNA sequencing and phylogenetic analysis. HTLV-II RFLP type a0 (Switzer classification) was associated with older age [adjusted odds ratio (OR) 1.06 per year of age, 95% confidence interval (CI) 1.02–1.09] and with Black (OR 5.24, 95% CI 1.90–14.47) and White (OR 4.43, 95% CI 1.67–11.75) race/ ethnicity. These data are consistent with an age–cohort effect for HTLV-II RFLP type a0 among older White and Black IDU and blood donors. This finding could be explained by an epidemic of non-a0 HTLV-II RFLP types among younger persons of Hispanic and other race/ethnicity, superimposed upon endemic HTLV-II RFLP type a0 among older Black and White persons.</abstract><qualityIndicators><score>7.136</score><pdfVersion>1.2</pdfVersion><pdfPageSize>534 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1173</abstractCharCount><pdfWordCount>5683</pdfWordCount><pdfCharCount>33400</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>178</abstractWordCount></qualityIndicators><title>Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</title><pii><json:string>S0042-6822(97)99009-7</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Virology</title><language><json:string>unknown</json:string></language><publicationDate>1998</publicationDate><issn><json:string>0042-6822</json:string></issn><pii><json:string>S0042-6822(00)X0097-9</json:string></pii><volume>242</volume><issue>2</issue><pages><first>425</first><last>434</last></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>virology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>biomedical research</json:string><json:string>virology</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>techniques d'exploration et de diagnostic (generalites)</json:string></inist></categories><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1006/viro.1997.9009</json:string></doi><id>6E7673E1DA630ABB7B43F1C7FD81517561532FDB</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/6E7673E1DA630ABB7B43F1C7FD81517561532FDB/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/6E7673E1DA630ABB7B43F1C7FD81517561532FDB/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6E7673E1DA630ABB7B43F1C7FD81517561532FDB/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©1998 Academic Press</p></availability><date>1998</date></publicationStmt><notesStmt><note type="content">Section title: Regular Article</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</title><author xml:id="author-0000"><persName><forename type="first">Edward L</forename><surname>Murphy</surname></persName><affiliation>To whom correspondence and reprint requests should beaddressed at Department of Laboratory Medicine, UCSF Box 0884,San Francisco, CA 94143-0884. Fax: (415) 502-0325. E-mail:murphy@labmed.ucsf.edu.</affiliation><affiliation>Departments of Laboratory Medicine, Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, California, 94143</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Renaud</forename><surname>Mahieux</surname></persName><affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Guy</forename><surname>de Thé</surname></persName><affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Fredj</forename><surname>Tekaia</surname></persName><affiliation>Unité de Génétique Moléculaire des Levures, Institut Pasteur, Paris, France</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Dannie</forename><surname>Ameti</surname></persName><affiliation>Westat Inc. Rockville, Maryland</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Jacqueline</forename><surname>Horton</surname></persName><affiliation>Westat Inc. Rockville, Maryland</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Antoine</forename><surname>Gessain</surname></persName><affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</affiliation></author><idno type="istex">6E7673E1DA630ABB7B43F1C7FD81517561532FDB</idno><idno type="DOI">10.1006/viro.1997.9009</idno><idno type="PII">S0042-6822(97)99009-7</idno></analytic><monogr><title level="j">Virology</title><title level="j" type="abbrev">YVIRO</title><idno type="pISSN">0042-6822</idno><idno type="PII">S0042-6822(00)X0097-9</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998"></date><biblScope unit="volume">242</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="425">425</biblScope><biblScope unit="page" to="434">434</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Molecular subtyping was used to investigate the epidemiology of human T-lymphotropic virus type II (HTLV-II) in the United States. Nested polymerase chain reaction of the HTLV-II long terminal repeat region followed by restriction fragment length polymorphism (RFLP) analysis was performed on HTLV-II seropositive subjects including 97 U.S. blood donors without major risk factors for HTLV-II infection, 53 injection drug users (IDU), and 10 American Indian blood donors. Three new HTLV-II RFLP types were confirmed with DNA sequencing and phylogenetic analysis. HTLV-II RFLP type a0 (Switzer classification) was associated with older age [adjusted odds ratio (OR) 1.06 per year of age, 95% confidence interval (CI) 1.02–1.09] and with Black (OR 5.24, 95% CI 1.90–14.47) and White (OR 4.43, 95% CI 1.67–11.75) race/ ethnicity. These data are consistent with an age–cohort effect for HTLV-II RFLP type a0 among older White and Black IDU and blood donors. This finding could be explained by an epidemic of non-a0 HTLV-II RFLP types among younger persons of Hispanic and other race/ethnicity, superimposed upon endemic HTLV-II RFLP type a0 among older Black and White persons.</p></abstract></profileDesc><revisionDesc><change when="1997-10-08">Modified</change><change when="1998">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/6E7673E1DA630ABB7B43F1C7FD81517561532FDB/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>YVIRO</jid><aid>99009</aid><ce:pii>S0042-6822(97)99009-7</ce:pii><ce:doi>10.1006/viro.1997.9009</ce:doi><ce:copyright type="full-transfer" year="1998">Academic Press</ce:copyright></item-info><head><ce:dochead><ce:textfn>Regular Article</ce:textfn></ce:dochead><ce:title>Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</ce:title><ce:author-group><ce:author><ce:given-name>Edward L</ce:given-name><ce:surname>Murphy</ce:surname><ce:cross-ref refid="VY979009A1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="VY979009FN1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Renaud</ce:given-name><ce:surname>Mahieux</ce:surname><ce:cross-ref refid="VY979009A2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Guy</ce:given-name><ce:surname>de Thé</ce:surname><ce:cross-ref refid="VY979009A2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Fredj</ce:given-name><ce:surname>Tekaia</ce:surname><ce:cross-ref refid="VY979009A3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Dannie</ce:given-name><ce:surname>Ameti</ce:surname><ce:cross-ref refid="VY979009A4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jacqueline</ce:given-name><ce:surname>Horton</ce:surname><ce:cross-ref refid="VY979009A4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Antoine</ce:given-name><ce:surname>Gessain</ce:surname><ce:cross-ref refid="VY979009A2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="VY979009A1"><ce:label>a</ce:label><ce:textfn>Departments of Laboratory Medicine, Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, California, 94143</ce:textfn></ce:affiliation><ce:affiliation id="VY979009A2"><ce:label>b</ce:label><ce:textfn>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</ce:textfn></ce:affiliation><ce:affiliation id="VY979009A3"><ce:label>c</ce:label><ce:textfn>Unité de Génétique Moléculaire des Levures, Institut Pasteur, Paris, France</ce:textfn></ce:affiliation><ce:affiliation id="VY979009A4"><ce:label>d</ce:label><ce:textfn>Westat Inc. Rockville, Maryland</ce:textfn></ce:affiliation><ce:footnote id="VY979009FN1"><ce:label>1</ce:label><ce:note-para>To whom correspondence and reprint requests should beaddressed at Department of Laboratory Medicine, UCSF Box 0884,San Francisco, CA 94143-0884. Fax: (415) 502-0325. E-mail:murphy@labmed.ucsf.edu.</ce:note-para></ce:footnote></ce:author-group><ce:date-received day="19" month="8" year="1997"></ce:date-received><ce:date-revised day="8" month="10" year="1997"></ce:date-revised><ce:date-accepted day="19" month="12" year="1997"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Molecular subtyping was used to investigate the epidemiology of human T-lymphotropic virus type II (HTLV-II) in the United States. Nested polymerase chain reaction of the HTLV-II long terminal repeat region followed by restriction fragment length polymorphism (RFLP) analysis was performed on HTLV-II seropositive subjects including 97 U.S. blood donors without major risk factors for HTLV-II infection, 53 injection drug users (IDU), and 10 American Indian blood donors. Three new HTLV-II RFLP types were confirmed with DNA sequencing and phylogenetic analysis. HTLV-II RFLP type a0 (Switzer classification) was associated with older age [adjusted odds ratio (OR) 1.06 per year of age, 95% confidence interval (CI) 1.02–1.09] and with Black (OR 5.24, 95% CI 1.90–14.47) and White (OR 4.43, 95% CI 1.67–11.75) race/ ethnicity. These data are consistent with an age–cohort effect for HTLV-II RFLP type a0 among older White and Black IDU and blood donors. This finding could be explained by an epidemic of non-a0 HTLV-II RFLP types among younger persons of Hispanic and other race/ethnicity, superimposed upon endemic HTLV-II RFLP type a0 among older Black and White persons.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0</title></titleInfo><name type="personal"><namePart type="given">Edward L</namePart><namePart type="family">Murphy</namePart><affiliation>Departments of Laboratory Medicine, Medicine and Epidemiology/Biostatistics, University of California San Francisco, San Francisco, California, 94143</affiliation><description>To whom correspondence and reprint requests should beaddressed at Department of Laboratory Medicine, UCSF Box 0884,San Francisco, CA 94143-0884. Fax: (415) 502-0325. E-mail:murphy@labmed.ucsf.edu.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Renaud</namePart><namePart type="family">Mahieux</namePart><affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Guy</namePart><namePart type="family">de Thé</namePart><affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fredj</namePart><namePart type="family">Tekaia</namePart><affiliation>Unité de Génétique Moléculaire des Levures, Institut Pasteur, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dannie</namePart><namePart type="family">Ameti</namePart><affiliation>Westat Inc. Rockville, Maryland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jacqueline</namePart><namePart type="family">Horton</namePart><affiliation>Westat Inc. Rockville, Maryland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Antoine</namePart><namePart type="family">Gessain</namePart><affiliation>Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1998</dateIssued><dateModified encoding="w3cdtf">1997-10-08</dateModified><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Molecular subtyping was used to investigate the epidemiology of human T-lymphotropic virus type II (HTLV-II) in the United States. Nested polymerase chain reaction of the HTLV-II long terminal repeat region followed by restriction fragment length polymorphism (RFLP) analysis was performed on HTLV-II seropositive subjects including 97 U.S. blood donors without major risk factors for HTLV-II infection, 53 injection drug users (IDU), and 10 American Indian blood donors. Three new HTLV-II RFLP types were confirmed with DNA sequencing and phylogenetic analysis. HTLV-II RFLP type a0 (Switzer classification) was associated with older age [adjusted odds ratio (OR) 1.06 per year of age, 95% confidence interval (CI) 1.02–1.09] and with Black (OR 5.24, 95% CI 1.90–14.47) and White (OR 4.43, 95% CI 1.67–11.75) race/ ethnicity. These data are consistent with an age–cohort effect for HTLV-II RFLP type a0 among older White and Black IDU and blood donors. This finding could be explained by an epidemic of non-a0 HTLV-II RFLP types among younger persons of Hispanic and other race/ethnicity, superimposed upon endemic HTLV-II RFLP type a0 among older Black and White persons.</abstract><note type="content">Section title: Regular Article</note><relatedItem type="host"><titleInfo><title>Virology</title></titleInfo><titleInfo type="abbreviated"><title>YVIRO</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19980315</dateIssued></originInfo><identifier type="ISSN">0042-6822</identifier><identifier type="PII">S0042-6822(00)X0097-9</identifier><part><date>19980315</date><detail type="volume"><number>242</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>239</start><end>445</end></extent><extent unit="pages"><start>425</start><end>434</end></extent></part></relatedItem><identifier type="istex">6E7673E1DA630ABB7B43F1C7FD81517561532FDB</identifier><identifier type="DOI">10.1006/viro.1997.9009</identifier><identifier type="PII">S0042-6822(97)99009-7</identifier><accessCondition type="use and reproduction" contentType="copyright">©1998 Academic Press</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Academic Press, ©1998</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000951 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000951 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6E7673E1DA630ABB7B43F1C7FD81517561532FDB
|texte= Molecular Epidemiology of HTLV-II among United States Blood Donors and Intravenous Drug Users: An Age–Cohort Effect for HTLV-II RFLP Type a0
}}
| This area was generated with Dilib version V0.6.31. |  |